Promising results of tests for a new drug that may help multiple sclerosis (MS) patients were announced at the recent annual meeting of the American Academy of Neurology in Boston.

A dual treatment option for a deadly strain of hepatitis C has received approval from the China Food and Drug Administration, opening a new market for the two drugs by New Jersey-based Bristol-Myers Squibb Co. The treatment involves the simultaneous use of two oral medications from Bristol-Myers Squibb, Daklinza and Sunvepra.

AstraZeneca, a leading lung cancer research company, said in a recent release that the European Commission (EC) has approved its Tagrisso (osimertinib), a once-daily tablet for adults with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer.

Four new topical anti-herpesvirus medicines under development by NanoViricides Inc. are set to undergo clinical trials on humans, potentially helping the company crack a billion-dollar market.

The Food and Drug Administration (FDA) told 14 U.S.-based companies to stop making false statements about products claiming to treat cancer.

Janssen-Cilag International NV (Janssen), a Johnson & Johnson company, said it recently won approval from the European Commission (EC) to combine its first-in-class CD38-directed monoclonal antibody Darzalex (daratumumab) with other drugs to treat adult multiple myeloma patients with a minimum of one previous therapy.

Doctors practicing at 1,600 U.S. hospitals will now find iteasier to stay credentialed in the Improvement in Medical Practice (Part IV), aprogram for board-certified physicians, thanks to a new partnership between theAmerican Hospital Association and the ABMS Multi-Specialty Portfolio Program.

A recent Health Affairs study suggests that primary care physicians spend 49% of their clinical time on face-to-face visits with patients and 51% on what study authors call “desktop medicine,” and payment policies should reflect that, according to the American Academy of Family Physicians, or AAFP.

The Food and Drug Administration has approved Horizon Pharma's supplemental new drug application to expand the use of Ravicti (glycerol henylbutyrate), an oral liquid used to treat urea cycle disorders (UCDs) in patients who are unable to manage the condition with dietary restriction or amino acid supplementation, to patients as young as 2 months old.

A posting on the American Cancer Society's website said the Food and Drug Administration has approved a new medication for adults undergoing treatment for acute myeloid leukemia (AML).

The FDA has issued a safety warning regarding the use of codeine and tramadol in children, a release posted on the American Academy of Family Physicians website said.

Vermont cancer advocates, survivors and care givers recently visited the Statehouse to encourage legislation that could help reduce the rate of cancer within the state as part of the American Cancer Society Cancer Action Network’s (ACS CAN) Cancer Action Day.

BioMarin Pharmaceutical Inc. recently agreed to a settlement with Par Pharmaceuticals surrounding Kuvan (sapropterin dihydrochloride) in which BioMarin will retain exclusive rights to the drug until Oct. 1, 2020.

The Food and Drug Administration (FDA) recently issued Merck a complete response letter for the company’s application for supplemental prescribing information on its labels for Januvia, Janumet and Janumet XR.

A new therapy that generates unique treatment for leukemia in children based on their DNA is undergoing a fast-track review process by the U.S. Food and Drug Administration (FDA).

The European Commission has approved two drugs to treat a type of non-small cell lung cancer.

Patients suffering from multiple myeloma, a cancer of the blood cells, may soon get a new treatment option if officials from the U.S. Food and Drug Administration and the European Medicines Agency expand XGEVA to treat the illness.

The U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) recently discussed nonacog beta pegol, a new treatment for hemophilia B, Novo Nordisk said in release.

Orexigen Therapeutics Inc. has reached an agreement to distribute weight-loss drug Mysimba in Italy.

The European Commission (EC) has authorized Pfizer’s Xeljanz oral medication to treat moderate to severe rheumatoid arthritis, which affects nearly 3 million people in Europe.